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In this study, the ability of porous silicon nanoparticles (PSi NPs) to entrap and deliver nitric oxide (NO) as an effective
antibacterial agent is tested against different Gram-positive and Gram-negative bacteria. NO was entrapped inside PSi
NPs functionalized by means of the thermal hydrocarbonization (THC) process. Subsequent reduction of nitrite in the
presence of D-glucose led to the production of large NO payloads without reducing the biocompatibility of the PSi
NPs with mammalian cells. The resulting PSi NPs demonstrated sustained release of NO and showed remarkable
antibacterial efficiency and anti-biofilm-forming properties. These results will set the stage to develop antimicrobial
nanoparticle formulations for applications in chronic wound treatment.
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Wound contamination by bacteria or other microor-
ganisms may cause a delay in or a deterioration of the
healing process [1,2]. Although bacteria are present in
most wounds, the body’s immune defense is generally
efficient in overcoming this contamination and supporting
successful healing. However, in some cases, such as
diabetic, immunocompromised or elderly patients, the
immune system requires assistance [3-6]. Typical treat-
ments for infection in these cases include antibiotics,
which can be applied directly to the wound or taken
orally. In cases of severe infection, intravenous admin-
istration is required to rapidly achieve dosages sufficient
to clear the bacterial load [7,8]. Recently, concerns have
arisen over the increased prevalence of antibiotic-resistant
bacteria such as methicillin-resistant Staphylococcus
aureus (MRSA), which is promoted by injudicious anti-
biotic use [3,9]. Serious and sometimes fatal cases of
antibiotic-resistant infections have occurred in hospitals
and community settings [10], and this is developing
into an important public health problem [8].
Recently, new antibacterial therapeutics based on nano-
materials have emerged for the treatment of infected
wounds [11-14]. For example, mesoporous silica has
been used as a nanocarrier to deliver antibacterial agents* Correspondence: nico.voelcker@unisa.edu.au
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in a controlled manner [15,16]. However, the further
development of antibiotic delivering nanoparticles (NPs)
has been hampered by increasing bacterial resistance to
conventional antibiotic candidates for the active agent
[3]. In the early 1990s, nitric oxide (NO) was considered
as an alternative antibiotic strategy for a wide range of
Gram-positive and Gram-negative bacteria [17,18]. NO is
produced by various cells resident in the skin as one of
the natural defenses of the immune system and should
therefore prove to be effective against pathogen invasion
while being tolerated by human skin [19]. The mechanism
of NO-mediated bactericidal actions is reasonably well
understood [19,20]. A major factor appears to be mem-
brane destruction via lipid peroxidation [9,17].
In order to harness the antibacterial power of NO,
however, this molecule must be loaded and trapped in a
suitable carrier. NO-loaded silica nanocarriers have been
synthesized using diazeniumdiolate NO donors [9]. The
NO loading capacity was directly influenced by NP size
[21]. These NPs showed antibacterial efficacy in a time-
and concentration-dependent manner [9,21] and reduced
biofilms composed of Gram-positive and Gram-negative
bacteria (≥5 and 2 log reduction, respectively) [22]. In an
alternative approach, Friedman and co-workers synthe-
sized NO-loaded silica nanocarriers using glucose for
the thermal reduction of nitrite to NO [23]. The sustained
release of NO from the silica NPs resulted in antimicrobials an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and Acinetobacter baumannii [4,23].
Porous silicon (PSi) is a high surface area, high porosity,
biocompatible, and bioresorbable form of silicon widely
employed in biomedical applications, including as NPs
[24-28]. The use of PSi NPs avoids the issues of toxicity
associated with silica-derived nanocarriers; further, NP
porosity can be easily tuned by manipulation of current
density [29,30]. Thermally hydrocarbonized porous silicon
(THCPSi) NPs have remarkable stability in physiological
environments and also show low cytotoxicity in vivo [25].
THCPSi elicits little inflammatory response [25,28]. Small
molecular drugs and peptides have been successfully
loaded into and released from THCPSi NPs, with some
promising results in the areas of drug delivery and multi-
modal bioimaging [24]. Due to these promising properties,
we have chosen THCPSi NPs as a nanocarrier for NO
and have explored the antibacterial efficacy of NO-loaded
NPs towards planctonic Escherichia coli, Pseudomonas
aeruginosa, and Staphylococcus aureus and a Staphylococ-
cus epidermidis biofilm. All of these pathogens can cause
primary skin and soft tissue infection [8,31,32]. We also




Silicon wafers (boron doped, p+ type, 0.01 to 0.02 Ω cm)
were obtained from Siegert Wafer GmbH (Aachen,
Germany). Ethanol (EtOH, 99.6 vol.%) was obtained
from Altia Plc. (Porkkalankatu, Finland), and hydrofluoric
acid (HF, 38%) from Merck GmbH (Darmstadt, Germany).
Sulfuric acid, sodium nitrite, Griess reagent, 4-amino-
5-methylamino-2′,7′-difluorofluorescein (DAF-FM), D-
glucose, potassium hydroxide, and phosphate-buffered
saline (PBS) tablets were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Tryptic soy broth (TSB; soybean-
casein digest) and nutrient agar were purchased from
Thermo-Scientific (Waltham, MA, USA). E. coli (ATCC
#25922), P. aeruginosa (ATCC #27853), S. epidermidis
(ATCC #35984), and S. aureus (ATCC #29213) were
obtained from the American Type Culture Collection
(Manassas, VA, USA). For mammalian cell culture, the
following reagents were used as received: 0.01 M PBS
pH 7.4 (Sigma-Aldrich), DMEM medium, fetal bovine
serum (FBS), L-glutamine, penicillin, streptomycin, ampho-
tericin B (all purchased from Life Technologies, Carlsbad,
CA, USA), propidium iodide (PI; Sigma-Aldrich), fluores-
cein diacetate (FDA; Sigma-Aldrich), lactate dehydrogenase
(LDH) cytotoxicity assay kit II (Abcam, Cambridge, UK),
and trypsin (0.05%, EDTA 0.53 mM, Life Technologies).
Cell culture media were prepared using ultrapurified water
supplied by a Milli-Q system (Millipore Co., Billerica,
MA, USA). NIH/3T3 mouse embryonic fibroblasts(ATCC #CRL-1658) from the American Type Culture
Collection were used in these experiments.
Fabrication of THCPSi NPs
THCPSi NPs were fabricated according to the previously
reported procedure [25] from p+ type (0.01 to 0.02 Ω
cm) silicon wafers by periodically etching at 50 mA/cm2
(2.2-s period) and 200 mA/cm2 (0.35-s period) in an
aqueous 1:1 HF(38%)/EtOH electrolyte for a total etching
time of 20 min. Subsequently, the THCPSi films were
detached from the substrate by abruptly increasing the
current density to electropolishing conditions (250 mA/
cm2, 3-s period). The detached multilayer films were
then thermally hydrocarbonized under N2/acetylene
(1:1, volume) flow at 500°C for 15 min and then cooled
down to room temperature under a stream of N2 gas.
The THCPSi membranes (1.3 g) were converted to NPs
using wet ball milling (ZrO2 grinding jar, Pulverisette 7,
Fritsch GmbH, Idar-Oberstein, Germany) in 1 decene
(18 mL) overnight. A size separation was performed by
centrifugation (1,500 RCF, 5 min) in order to achieve a
narrow particle size distribution.
Preparation of NO/THCPSi NPs
Sodium nitrite (10 mM) dissolved in 50 mM PBS (pH 7.4)
was mixed with glucose 50 mg/mL. The THCPSi NPs
were then added to this buffer solution at different con-
centrations (ranging from 0.05 to 0.2 mg/mL). Subse-
quently, the suspension was sonicated for 5 min to
ensure particle dispersion and then stirred for 2 h. Upon
NO incorporation, the THCPSi NPs were centrifuged at
8,000 RCF for 10 min for collection. Finally, after remov-
ing the supernatant, the THCPSi NP pellet was dried by
heating at 65°C overnight. The drying temperature was
held at 70°C to avoid glucose caramelization [23,33,34].
An alternative drying procedure, overnight lyophilization
(FD1 freeze dryer, Dynavac Co., MA, USA), was also
assessed, as described in the text [23].
Glucose/THCPSi NPs and sodium nitrite/THCPSi NPs
were also prepared following the same procedure as for
the NO/THCPSi NPs but omitting either sodium nitrite
or D-glucose during NP loading, respectively. All prepared
NPs were kept at ambient conditions and were dispersed
via sonication for 5 min in PBS before use.
Pore structure analysis
The pore volume, average pore diameter, and specific
surface area of the THCPSi NPs were calculated from
nitrogen sorption measurements on a TriStar 3000 por-
osimeter (Micromeritics Inc., Norcross, GA, USA).
Scanning electron microscopy
Morphological studies of THCPSi NPs were carried out
by means of scanning electron microscopy (SEM) on a
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collecting secondary electrons at 30-kV beam energy under
high vacuum of 6 × 10−4 Pa. Energy-dispersive X-ray spec-
troscopy (EDX) measurements were performed using a
Link 300 ISIS instrument from Oxford Instruments
(detector Si(Li), 30-kV beam energy, resolution 60 eV;
Abingdon, Oxfordshire, UK). The samples were prepared
by fixing the NPs to the microscope holder, using a con-
ducting carbon strip. In order to conduct SEM and EDX
analysis of NO/THCPSi NPs treated and untreated with
E. coli, colonies at the desired growth stage were fixed
by formaldehyde (4 v/v%) for 2 h on round graphite
disks. After rinsing twice with PBS, the disks were
attached on a SEM holder and were observed by using
the Quanta™ 450 FEG SEM and the Link 300 ISIS EDX
(Oxford Instruments).
Dynamic light scattering
The mean particle size and size distribution of NPs were
determined by dynamic light scattering (DLS; Zetasizer
Nano ZS, Malvern Instruments, Malvern, UK). The analysis
was carried out at a temperature of 25°C using NPs dis-
persed in ultrapurified water. Every sample measurement
was repeated 15 times.
Infrared spectroscopy
Diffuse reflectance infrared Fourier transform (DRIFT)
spectra were acquired using a Thermo Nicolet Avatar
370MCT (Thermo Electron Corporation, Waltham, MA,
USA) instrument. A smart diffuse reflectance accessory
was used for all samples embedded within KBr pellets.
The spectra were recorded and analyzed using OMNIC
version 7.3 software (Thermo Electron Corp., Waltham,
MA, USA). For each spectrum, 128 scans were averaged
in the range of 4,000 to 800 cm−1 with a resolution of
4 cm−1. In addition, dipole moments of the chemicals
were calculated using the Millsian 2.1 Beta (Millsian, Inc.,
Cranbury, NJ, USA). Background spectra were blanked
using a suitable clean silicon wafer. All spectra were run
in dry air to remove noise from CO2 and water vapor.
Generation of NO
A calibration curve for NO was obtained by preparing a
saturated solution of NO as described previously by
Mesároš et al. [35]. Briefly, 10 mL of PBS (pH 7.4) was
degassed using an Ar purge for 60 min. Subsequently,
NO was generated by adding 20 mL of 6 M sulfuric acid
slowly to 2 g of sodium nitrite in a twin-neck round-
bottom flask, which was connected via rubber tubing to
a Büchner flask containing KOH solution (to remove
NO degradation products, 10% v/v). The Büchner flask
was then connected to the flask containing degassed
PBS. The NO gas produced was bubbled through the
degassed PBS (held at 4°C) for 30 min to produce asaturated NO solution. The solubility of NO in PBS at
atmospheric pressure is 1.75 ± 0.02 mM [35-37]. Using
Griess reagent [13], our solution was found to have a
concentration of 1.87 mM at 37°C.
Colorimetric assay of nitrite
The presence of nitrite compounds can be detected by
the Griess reaction, which results in the formation of a
characteristic red pink color. Nitrites react with sulfanilic
acid to form a diazonium salt, which then reacts with
N-alpha-naphthyl-ethylenediamine to form a pink azo dye
[38,39]. A calibration curve was prepared using dilutions
of sodium nitrite between 0.43 and 65 μM in PBS
(pH 7.4, temperature 37°C) mixed with equal volumes
of the prepared Griess reagent according to the manu-
facturer’s instructions. The absorbance of the solutions
at 540 nm was measured on a HP8453 PDA UV/VIS
spectrophotometer (Agilent, Santa Clara, CA, USA).
Fluorimetric determination of NO
To detect the release of NO from PSi NP, the DAF-FM
assay was used. DAF-FM is non-fluorescent until it reacts
with NO to form a fluorescent benzotrizole. DAF-FM pos-
sesses good specificity, sensitivity (approximately 3 nM)
and is simple to use [23,36]. It does not react with the
other nitrogen oxides (i.e., NO2
− and NO3
−) and reactive
oxygen species (i.e., O2
− and H2O2) [23].
Fluorescence spectra for all samples were acquired using
a LS 55 spectrofluorometer (PerkinElmer, Waltham, MA,
USA) with slit widths set at 2.5 nm for both excitation and
emission; the photomultiplier voltage was set to 775 V, and
a wavelength of 495 nm was used for excitation and
515 nm for emission. In order to prepare an approximate
1 mM stock DAF-FM solution, 1 mg of DAF-FM was dis-
solved in 250 μL DMSO and then the stock solution
(10 μL) was mixed with 90 μL PBS (pH 7.4). Fluorescence
was expressed as arbitrary fluorescence units and was mea-
sured at the same instrument settings in all experiments.
For the fluorescence-based measurements of NO concen-
tration, a calibration curve was prepared using dilutions of
saturated NO solution in PBS between 0.00 and 1.87 mM
in PBS (pH 7.4, 37°C). Fresh DAF-FM stock solution was
added to the PBS and immediately mixed in an Eppendorf
tube in the darkness using a shaker for 2 min and then
transferred into a quartz cuvette with a stopper, and the
fluorescence was measured after a 5-min incubation.
Nitric oxide release from NO/THCPSi NPs
The prepared NO/THCPSi NPs (0.1 mg/mL) were added
to PBS (1 mL), sonicated, and mixed using a test tube
shaker. After incubation at 37°C for the sampling inter-
val times specified in the text, the NPs were centrifuged
at 12,000 RCF for 5 min and then the supernatant con-
taining the released NO from the NPs was separated and
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mately 1 mM) for 2 min at room temperature in the
darkness on a test tube shaker (approximately 0.1 RCF).
The supernatant containing NO and DAF-FM was
subsequently transferred into a cuvette, and fluores-
cence intensities were measured as described above.
The amount of the released NO was calculated using
the fluorimetric DAF-FM calibration curve.
Determination of antimicrobial activity
P. aeruginosa, E. coli, and S. aureus were cultured over-
night at 37°C in TSB and diluted to a concentration of
108 colony-forming units per milliliter (CFU/mL) based
on turbidity (OD600) and further diluted to 10
4 CFU/mL
and 1 mL treated with different concentrations of NO/
THCPSi NPs or glucose/THCPSi NPs (control). As a
further control, NO/THCPSi NPs (0.1 mg/mL) were
added to 0.5 mL of PBS, sonicated for 5 min and then
incubated for 2 h to remove NO, centrifuged (12,000
RCF for 5 min), and NO-depleted NO/THCPSi NPs
dried at 65°C overnight. Bacteria not treated with NPs
were used as negative controls in each experiment.
The NP samples were incubated for 2 h, 4 h (S. aureus;
0.05, 0.1, or 0.2 mg/mL concentration of NPs), and 24 h
(P. aeruginosa, E. coli, and S. aureus; 0.1 mg/mL concen-
tration of NPs) at 37°C. S. aureus were then serially diluted
and spread-plated on nutrient agar. Bacterial viability was
assessed by counting the number of colonies formed
on the agar plate. The colony count was normalized
by considering the untreated colony (negative) as 100% of
bacteria viability. The viability of E. coli and P. aeruginosa
after 24 h was determined by turbidity measurements
(OD600nm), taking into account background caused by the
NPs themselves.
Effect of NO/THCPSi NPs on established biofilms
The reduction in total viable cells recovered from estab-
lished S. epidermidis biofilms treated with NO/THCPSi
NPs was compared to the control biofilms of the same
species not treated with the NPs. Glass microscope
slides were cut into pieces with surface areas of 24 mm2.
The glass pieces were cleaned with 70% ethanol and dried.
S. epidermidis was cultured at 37°C in TSB overnight
and diluted to 106 CFU/mL. The 106 CFU/mL microbial
suspension was then added to each tube containing the
glass slide pieces. The vials containing bacteria, broth,
and glass slide pieces were placed in a 37°C incubator for
biofilm formation. After 24 h, the glass slide pieces were
removed from the nutrient broth, rinsed twice in sterile
PBS, and individually transferred into new Eppendorf
tubes containing a fresh suspension 1 mL of 0.1 mg/mL
NO/THCPSi NPs and THCPSi NPs (control) in PBS and
returned to the 37°C incubator. After 24 h, the tubes
containing glass slide pieces were sonicated in a 125-Wultrasonic cleaner for 5 min to remove the biofilm-forming
cells from the slide. The resulting bacterial suspension
was subjected to serial tenfold dilutions, and 100 μL of
appropriate dilutions was plated onto agar plates, which
were then incubated at 37°C overnight. The total number
of colonies that grew on each plate was counted, and
the number of viable biofilm bacteria removed from
each slide was determined.
Mammalian cell viability assay
The cytotoxicity of the NO/THCPSi NPs was evaluated
using NIH/3T3 fibroblast cells. The cells were maintained
in DMEM supplemented with 10% FBS and 2 mM L-
glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin,
and incubated at 37°C with 5% CO2.
All mentioned procedures for the preparation of NO/
THCPSi NPs and glucose/THCPSi NPs were done under
sterile conditions within a biological safety cabinet (Bio-
cabinet, Aura 2000, Microprocessor Automatic Control,
Firenze, Italy).
The NIH/3T3 cells were trypsinized and then seeded
into polystyrene 96-well plates (Nalge Nunc International,
Penfield, NY, USA) at a density of 3 × 104 cells/mL
and then after 24 h, the cultured cells were incubated
with NO/THCPSi NPs, glucose/THCPSi NPs, and
THCPSi NPs at four different concentrations from
0.05 to 0.2 mg/mL for 48 h.
After the incubation period, the culture medium was
separated from the cultured cells and subjected to a LDH
assay that was carried out following the manufacturer’s in-
structions. Moreover, a FDA-PI assay was performed on
the cultured cells remaining in the wells. The cells were
incubated with fresh medium before adding final concen-
trations of 15 μg/mL FDA and 5 μM PI for 3 min at 37°C
to count the live and dead cells, respectively, using a fluor-
escence microscope (Eclipse, Ti-S, Nikon, Tokyo, Japan)
and determine the percentage of live cells. All experi-
ments were repeated at least three times.
Statistics
For the NO release tests and bactericidal assays conducted
in the related media, n = 3 and the data are expressed as
mean values ± standard deviation. Statistical significance
between populations was determined by one-way ANOVA
followed by Tukey’s multiple comparison post hoc analysis
(GraphPad Prism® software). Data from both the FDA-
PI and LDH cytotoxicity assays are presented as mean
values ± standard error of the mean.
Results and discussion
Characterization of NO/THCPSi NPs
THCPSi NPs were prepared using PSi films fabricated
by pulsed electrochemical etching of silicon wafers
with (HF; 38%) and ethanol. The preparation and
Figure 1 DRIFT absorbance spectra for PSi NPs. (a) THCPSi NPs,
(b) glucose/THCPSi NPs, (c) sodium nitrite/THCPSi NPs, and (d)
NO/THCPSi NPs.
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been described in detail elsewhere [24-26]. Briefly,
THCPSi NPs were prepared by using wet ball milling of
the multilayer THCPSi films. The described method
produced PSi NPs with an average pore diameter of
9.0 nm, a specific surface area of 202 m2/g, and a pore
volume of 0.51 cm3/g. The NPs were NO-loaded via
glucose-mediated reduction of nitrite during incubation
with THCPSi NPs. Two methods of thermal reduction
were assessed: one using lyophilization and one
employing heat [23]. The hydrodynamic diameter of
the THCPSi NPs and NO/THCPSi NPs was found to
be 137 and 142 nm, respectively, according to dynamic
light scattering measurements (Additional file 1: Figure S1).
The measured zeta (ζ)-potentials of the THCPSi and
NO/THCPSi NPs were −30 and −42 mV, respectively.
DRIFT spectroscopy was used to chemically characterize
PSi NPs. In order to scrutinize the nitrite reduction reac-
tion used to prepare the NO/THCPSi NPs, DRIFT spectra
of the prepared THCPSi NPs (control a), glucose/THCPSi
NPs (control b), sodium nitrite/THCPSi NPs (control c),
and NO/THCPSi NPs were obtained (see Figure 1). The
DRIFT spectra obtained from all PSi NPs showed a com-
mon set of bands, such as C-H vibration (2,856 cm−1),
related to the thermal hydrocarbonization [40]. The
NO/THCPSi NPs spectrum presented a N-O stretching
vibration (dipole moment 0.4344 Debye) at 1,720 cm−1,
indicating entrapment of NO within the NPs [41].
Moreover, in the spectra of the NO/THCPSi NPs and
sodium nitrite/THCPSi NPs, an intense combination
band corresponding to O-N =O around 2,670 cm−1 was
observed [42]. The band related to the O-N =O bending
vibration (dipole moment 3.8752 Debye) in the NO/
THCPSi NPs is likely to be the result of unreduced
sodium nitrite remaining in the NPs. In addition, the
presence of the O-H stretching vibrations for NO/
THCPSi NPs and glucose/THCPSi NPs indicates the
presence of glucose on the NO/THCPSi NPs. A 35%
decrease in nitrite band intensity compared to sodium
nitrite/THCPSi NPs (normalized between spectra based
on C-H vibration at 2,856 cm−1) is evidence of the
reduction reaction of nitrite during preparation of NO/
THCPSi NPs.
NO release from NO/THCPSi NPs
Sugar-mediated thermal reduction of nitrite-loaded TH
CPSi NPs produces and entraps NO inside of THCPSi
NPs [18,33]. NO formation is the consequence of chem-
ical acidification and redox conversion. Upon drying,
D-glucose is oxidized, and correspondingly, nitrite within
the pore structure is converted to NO [43]. The dried
glucose layer also assists in trapping inside the pores.
The entrapped NO is retained within the pores of the
NPs until exposed to moisture [18,23].
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was assessed in PBS (pH 7.4) at 37°C by monitoring
conversion of DAF-FM to fluorescein via fluorimetry.
DAF-FM conversion requires NO and does not occur
in the presence of other reactive oxygen/nitrogen species.
The results are shown in Figure 2. NO/THCPSi NPs
prepared by both heating and lyophilization protocols
were tested. Release of NO from NO/THCPSi NPs
occurred predominately in the first 2 h of the monitor-
ing period. Although NPs created by either methods
displayed the same maximal release of NO into the PBS
medium after 2-h incubation, release profiles obtained
using NPs prepared using the lyophilization protocol
showed an initial burst release phase (within the first
30 min). In contrast, glucose/THCPSi NPs, sodium nitrite/
THCPSi NPs, PBS, and sodium nitrite solution controls
showed no NO release (Additional file 1: Figure S2), dem-
onstrating that the NO release indeed only occurs upon
nitrite reduction. In reports describing other NO-releasing
mesoporous nanocarriers [9,23], only a short period of
continuous release is noted, suggesting that the NO/
THCPSi NPs described here possess a higher capacity
for sustained release of NO.
Antibacterial efficacy of NO/THCPSi NPs
Wound contamination by pathogens such as P. aeruginosa,
S. aureus, and E. coli is responsible for a significant morbid-
ity load, particularly in burns and immunocompromised
patients [8,31,32]. Initial tests of the antibacterial activity
of NO/THCPSi NPs (fabricated by the heating method)
were performed against planctonic P. aeruginosa, E. coli,
and S. aureus (104 CFU/mL for all) treated with 0.1 mg/mL
of NPs for 24 h. Compared to the controls (the bacteria
cultured without NPs and bacteria treated with glucose/
THCPSi NPs), the NO/THCPSi NPs showed significant
growth inhibition against all three bacteria species testedFigure 2 NO release from NO/THCPSi NPs as a function of time.
NO/THCPSi NPs prepared using the heating protocol (black cross-lines)
and the lyophilization protocol (red empty triangles). n = 3; mean ±
standard deviation shown.(see Figure 3). After the 24-h incubation with 0.1 mg/mL of
NO/THCPSi NPs, the bacterial counts of P. aeruginosa, S.
aureus, and E. coli cultures were reduced approximately 1
log in comparison with bacteria cultured in the absence
of NPs.
Further experiments showed that growth inhibition by
NO/THCPSi NPs against planktonic S. aureus was evident
as early as 2 to 4 h after NP treatment (Figure 4). After
2 h, the bacterial counts were reduced by 0.52 log
compared to the control (bacteria only), and after 4 h,
a further reduction occurred (1.04 log). In contrast,
glucose/THCPSi NPs supported S. aureus proliferation
at the same incubation times. Growth inhibition of S.
aureus was sensitive to the dose of NO/THCPSi NPs
applied (Figure 4). When higher concentrations of NO/
THCPSi NPs were applied, the S. aureus bacterial load
decreased by 1.3 log. It should be noted that a by-product
of increasing NP concentration is glucose supplementa-
tion, which may be reflected by the increase in bacterial
density in cultures treated with glucose/THCPSi NPs.
Cultures treated with NO/THCPSi NPs, however, showed
no such upward trend in bacterial growth rate, suggesting
that the release of NO was able to counter any influence
wrought by additional glucose provided by NO/THCPSi
NPs. Therefore, these results indicate that the NO
released form the NO/THCPSi NPs is an effective anti-
microbial agent against medically relevant Gram-positive
and Gram-negative bacteria.
Figure 5 shows the SEM images and EDX spectra of
E. coli treated with NO/THCPSi NPs compared with an
untreated control. Single NPs and NP aggregates were
evident in the SEM images on the bacteria and on the
background surface. The presence of the NO/THCPSi
NPs on the surface of the cell membrane of the E. coliFigure 3 Inhibitory effect of NO/THCPSi NPs (0.1 mg/mL) on
bacterial cultures. E. coli (blue bars), S. aureus (yellow bars), and
P. aeruginosa (green bars) after 24 h of incubation in TSB medium
(37°C, initial bacteria density 104 CFU/mL; n = 3; mean ± standard
deviation shown).
Figure 4 Time-based inhibition of S. aureus by NO/THCPSi NPs. S. aureus was treated with glucose/THCPSi NPs (blue columns) and NO/THCPSi
NPs (orange columns) at different NP concentrations after (a) 2 h and (b) 4 h (initial bacteria density 104 CFU/mL). Statistically significant inhibition as
compared with control (*P < 0.05, **P < 0.01; n = 3; mean ± standard deviation shown).
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characteristic for Si (Figure 5c).
Anti-biofilm efficacy of NO/THCPSi NPs
S. epidermidis biofilms were exposed to the NO/THCPSi
NPs at a concentration of 0.1 mg/mL and showed a 0.28
log (47%) reduction in total viable cells compared to the
control samples (bacteria only). THCPSi NPs that were
not loaded with NO applied at the same concentration
produced a negligible reduction in the biofilm density,
indicating that the NO released from the prepared NO/Figure 5 SEM images and EDX spectra of NO/THCPSi NP-treated E. co
the E. coli only, (c) EDX spectrum of NO/THCPSi NP-treated E. coli, and (d)
on bacterial surface (yellow overlay). NPs on the bacterial surface and settleTHCPSi NPs was the primary cause of any antimicrobial
action. In comparison with the high doses of NO donor
silica NPs reportedly required for the treatment of S.
epidermidis biofilms [22], the sugar-mediated NO/THCPSi
NPs showed effective biofilm reduction at a fractional dose.
Cytotoxicity of NO/THCPSi NPs to NIH/3T3 fibroblast cells
The biocompatibility of THCPSi NPs has been previously
reported by Santos and co-workers [25,28], where cytotox-
icity, oxidative, and inflammatory responses were studied
for a variety of mammalian cell lines. The toxicity of NO/li. (a) SEM image of NO/THCPSi NP-treated E. coli, (b) SEM image of
EDX spectrum of untreated E. coli as a control. EDX analysis performed
d on the background are indicated by red arrows.
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different concentrations (0.05 to 0.2 mg/mL) over 48 h was
evaluated using the NIH/3T3 cell line, which is one of the
most commonly used fibroblast cell lines and often used as
a model for skin cells. Two viability assays were used for
toxicity studies: LDH and fluorescein diacetate-propidium
iodide (FDA-PI). As shown in Figure 6, the results from the
LDH assay showed well over 90% viability for all NP types
up to 0.1 mg/mL. However, increasing the concentration of
NO/THCPSi NPs to 0.2 mg/mL reduced the viability of
NIH/3T3 cells to 92%. In contrast, the viability of fibroblast
cells incubated with glucose/THCPSi NPs and THCPSi
NPs at 0.15 and 0.2 mg/mL remained over 95%. The results
of the FDA-PI assay (Additional file 1: Figure S3) were con-
sistent with those obtained using the LDH assay.
The cytotoxicity of THCPSi NPs has been reported to
be concentration dependent [25,27], and increased con-
centrations of NO/THCPSi NPs did raise cytotoxicity.
However, the cytotoxicity of THCPSi NPs on fibroblast
cells is much less than observed for silica NPs, silver
NPs, and other clinical antiseptic wound treatments
[3,11,44,45]. We note that dosage optimization (e.g.,
concentration of 0.1 mg/mL) enables a balance between
high antibacterial efficacy and low toxicity towards
mammalian cells present in a wound environment to be
achieved.
Conclusions
The present work demonstrates the capacity of THCPSi
NPs to be loaded with NO by utilizing the sugar-
mediated thermal reduction of nitrite. These NO/
THCPSi NPs possess the capacity to deliver NO at
therapeutic levels in a more sustained manner than pre-
viously demonstrated using NO-releasing NPs. NO de-
livered from the NPs was effective at killing pathogenic
P. aeruginosa, E. coli, and S. aureus after only 2 h of in-
cubation. After 24 h, the bacterial load was reduced byFigure 6 Toxicity of the NPs to NIH/3T3 fibroblasts using the
LDH assay after 48-h incubationc NO/THCPSi NPs (red bars),
glucose/THCPSi NPs (blue bars), and THCPSi NPs (yellow bars).
Viability measures normalized to no NP control samples (n = 3;
mean ± standard deviation shown).approximately 1 log. In addition, NO/THCPSi NPs
showed effectiveness at inhibiting the growth of biofilm-
based microbes. The NO/THCPSi NPs demonstrated a
47% reduction in S. epidermidis biofilm viability com-
pared to the control samples. On the other hand, NIH/
3T3 mouse fibroblasts incubated with the same concen-
tration of NO/THCPSi NPs for 48 h maintained high
cell viability. In summary, our results suggest that NO/
THCPSi NPs are useful as a nanocarrier for NO release
to treat bacterial infections in wounds. Future studies
will focus on enhancing NO release and identifying the
interactions between NO/THCPSi NPs and bacterial cell
membranes.Additional file
Additional file 1: Figure S1. Representative scanning electron microscope
(SEM) image of THCPSi NPs (a) and DLS size distribution of THCPSi NPs (b).
Figure S2. fluorescence detection of NO released from NO/THCPSi NPs. (a)
Calibration curve obtained by adding aliquots of saturated NO solution
(1.87 mM) to PBS containing DAF-FM indicator. (b) NO detection from NO/
THCPSi NPs, glucose/THCPSi NPs (control), sodium nitrite/THCPSi NPs
(control), sodium nitrite (control), and PBS (control) prepared using the
heating protocol after 2 h of the release process at 37°C. Figure S3.
cytotoxicity of (A) NO/THCPSi NPs, (B) glucose/THCPSi NPs, (C) THCPSi NPs,
and (D) no treatment control towards NIH/3T3 cells as measured by FDA-PI
assay after 48 h. The roman numbers represent the different concentrations
of the NPs (I 0.05 mg/mL, II 0.1 mg/mL, III 0.15 mg/mL, and IV 0.2 mg/mL).Abbreviations
CFU: colony-forming unit; DAF-FM: 4-amino-5-methylamino-2',7'-
difluorofluorescein; FDA: fluorescein diacetate; FBS: fetal bovine serum; glucose/
THCPSi NPs: glucose-loaded thermal hydrocarbonized nanoparticles; LDH: lactate
dehydrogenase; MRSA: methicillin-resistant Staphylococcus aureus; NO/THCPSi
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PI: propidium iodide; PSi: porous silicon; THC: thermal hydrocarbonized/
hydrocarbonization; TSB: tryptic soy broth.Competing interests
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